Vosoritide for Achondroplasia Explained
For most of the history of achondroplasia, care has meant watching for complications and treating them as they appear. Vosoritide is a medicine that acts on the signalling pathway involved in the slowed bone growth of achondroplasia, and it raises real questions for families: what it does, what it does not do, and whether it is right for their child.
This page sets out what the regulators have published about it in plain terms. It is not a recommendation for or against treatment. That decision belongs to a family and a specialist team who know the child.
What vosoritide is
Vosoritide is a prescription medicine sold under the brand name Voxzogo. The European Medicines Agency describes it as a treatment for achondroplasia in patients aged 4 months and older whose bones are still growing. In regulatory language, it is for children whose epiphyses, the growth plates near the ends of the long bones, have not yet closed (European Medicines Agency).
It was designated an orphan medicine, the term used for medicines developed for rare conditions, and received a marketing authorisation valid throughout the European Union on 26 August 2021.
How it works
Achondroplasia is caused by a change in a gene called FGFR3, which helps regulate bone growth. In achondroplasia this gene is, in the EMA's words, permanently switched on. That slows the growth of bone at the growth plates, which is why the long bones of the arms and legs are shorter. You can read more about this in achondroplasia explained and is restricted growth genetic?
Vosoritide binds to a different receptor, called natriuretic peptide receptor type B (NPR-B). Activating that receptor reduces the activity of the FGFR3 pathway, which lets bone grow faster than it otherwise would. Put simply, it does not remove the brake, but it pushes back against it.
What the trials showed
The EMA summary describes two placebo-controlled studies:
- In a study of 121 children aged 5 to 17 years with confirmed achondroplasia, children given vosoritide grew about 1.57 cm more over a year than those given placebo, and the results suggested the improvement in growth was maintained.
- In a second study of 75 children aged from 4 months to under 5 years, children given vosoritide had a greater average improvement in height Z-score after one year, and grew about 0.8 cm more over the year than those given placebo.
A height Z-score compares a child's height with the average expected for their age and sex. It is a close cousin of the percentiles described in growth charts explained.
It is worth being clear about what these numbers measure. They describe a faster rate of growth while treatment is taken. The EMA notes that this may increase final adult height, which could make some daily activities easier. The EMA summary reports growth rate and height outcomes; it does not report effects on other complications of achondroplasia. Routine monitoring, such as that described in common orthopaedic issues, still matters whatever a family decides about treatment.
How it is given
According to the EMA, vosoritide is:
- Given as an injection under the skin once a day, ideally at around the same time each day, changing the injection site each time.
- Dosed according to the child's body weight.
- Started and supervised by a doctor experienced in growth disorders or abnormal bone growth.
- Only started once achondroplasia has been confirmed by genetic testing, and stopped when the child is not likely to grow any further.
- Something a parent or carer can give at home once they have been properly trained.
A daily injection for many years is a significant commitment for a child and a family. It is worth asking your specialist team how the routine would fit around school, holidays and your child's own feelings about it.
Side effects
The EMA lists the most common side effects, each affecting more than 1 in 10 people, as injection site reactions (such as swelling, redness, itching or pain), vomiting and decreased blood pressure. It considers these side effects manageable and reports that the safety profile in children under 5 is similar to that in older children. The full list of side effects and precautions is in the package leaflet, which your pharmacist or specialist can go through with you.
Where things stand in the UK
The UK position has been less settled than the European one. NICE, which assesses whether medicines should be offered on the NHS in England, began work on an appraisal of vosoritide for treating achondroplasia in people aged 4 months and over. In November 2025 NICE suspended that appraisal. It explained that the manufacturer had said it was no longer pursuing a marketing authorisation from the UK medicines regulator (the MHRA) for this indication at that time, and that NICE cannot make recommendations for treatments without one. NICE says it will continue to monitor developments and update interested parties if the situation changes (NICE).
Because this can change, the most reliable way to find out what is available for your child now is to ask the specialist team who manages their care. Support organisations such as the Restricted Growth Association UK can also help families understand their options.
Questions to ask your specialist team
- Is my child eligible, and what would treatment involve week to week?
- What could we realistically expect, and how would progress be measured?
- Is the medicine available to us here, and through which route?
- Which other parts of my child's care would carry on unchanged?
- What happens if we start and later decide to stop?
Common questions
What is vosoritide?
A prescription medicine, brand name Voxzogo, for children with achondroplasia whose bones are still growing. It is a daily injection under the skin that works on the pathway that slows bone growth in achondroplasia.
Who can have vosoritide?
In the European Union it is authorised from 4 months of age until the growth plates close, once achondroplasia has been confirmed by genetic testing. It is not used for other forms of restricted growth.
Does vosoritide cure achondroplasia?
No. It does not change the underlying genetic variant. It increases the rate of growth while it is being taken.
What are the common side effects?
Injection site reactions, vomiting and decreased blood pressure are the most commonly reported. Your specialist team will explain how these are monitored.
Is vosoritide available on the NHS?
The position is still developing. NICE suspended its appraisal in November 2025, so ask your child's specialist team what applies to you today.
In summary
Vosoritide is a medicine that acts on the pathway that slows bone growth in achondroplasia. In trials it increased growth rate while children were taking it, it is given as a daily injection, and its common side effects are considered manageable. It is not a cure and does not replace routine monitoring. Access in the UK remains uncertain, so your specialist team is the best guide to what is possible for your child. For background, start with achondroplasia explained or restricted growth in children.